6 months ago
TNGX
AnalystsCharles ZhuCharles Zhu's Stock Forecasts
AnalystsCharles Zhu
Sectors:
Industries:
Analyst Ranking
Top 20%
#1034 out of 5254 analysts
Average Return
+40.33%
Win Rate
50%9 out of 18
Risk vs Reward
Poor
Good
Charles Zhu's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Tango Therapeutics IncTNGX | +255.44% | $7.50 | $26.64 | 2025-10-24 - 2026-04-17 | Strong Buy |
Tango Therapeutics IncTNGX | +183.04% | $2.83 | $8.01 | 2024-11-07 - 2025-11-06 | Strong Buy |
Ideaya Biosciences IncIDYA | +162.81% | $17.21 | $45.23 | 2023-03-08 - 2024-03-07 | Strong Buy |
Ideaya Biosciences IncIDYA | +134.58% | $12.52 | $29.37 | 2022-09-13 - 2023-09-12 | Strong Buy |
Merus NvMRUS | +113.41% | $22.96 | $49.00 | 2023-08-08 - 2024-08-07 | Strong Buy |
Charles Zhu Analyst Color
Get additional color on Charles Zhu's coverage of popular stocks
Charles Zhu's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tango Therapeutics IncTNGX | 4 | Strong Buy | $12.00 | -54.95% | Maintains | 6 months ago |
Merus NvMRUS | 4 | Hold | $97.00 | +7.78% | Downgrades | 7 months ago |
Crescent Biopharma IncCBIO | 1 | Buy | $22.00 | +3.38% | Initiates Coverage On | 10 months ago |
Macrogenics IncMGNX | 2 | Strong Buy | $12.00 | N/A | Upgrades | 2 years ago |
Nuvalent IncNUVL | 1 | Strong Buy | $56.00 | N/A | Initiates Coverage On | 3 years ago |
Protara Therapeutics IncTARA | 1 | Strong Buy | $22.00 | N/A | Assumes | 3 years ago |
Cogent Biosciences IncCOGT | 3 | Strong Buy | $26.00 | N/A | Reiterates | 3 years ago |
Ideaya Biosciences IncIDYA | 2 | Strong Buy | $32.00 | N/A | Reiterates | 3 years ago |
Point Biopharma Global IncPNT | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.